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Abstract 
Human brain pyroglutamyl peptidase (PAPI; EC 3.4.19.3) is an omega exopeptidase which 
cleaves pyroglutamic acid from the N-terminus of bioactive peptides and proteins. It plays an 
important role in the processing and degradation of regulatory peptides such as thyrotropin 
releasing hormone (TRH) and luteinizing hormone releasing hormone (LHRH). To gain further 
insights into its performance in vivo and suggest possible applications, such as peptide 
processing or sequencing, this study focuses on the in vitro stability properties and Michaelis-
Menten kinetics of the recombinant wild type enzyme and a single-site mutant, Tyr147→Phe 
(Y147F). 
 
At 60ºC in 50mM potassium phosphate buffer, pH 8.0, recombinant PAPI underwent a first-order 
decay constant with a k value of 0.046 ± 0.002 min-1 and a half-life of 15 min. PAPI was unstable 
to most of the water-miscible solvents tested (dimethyl sulphoxide, methanol, acetone, 
tetrahydrofuran, acetonitrile, dimethyl formamide and ethanol) even at low v/v concentrations. 
Methanol and dimethyl sulphoxide were the least injurious to PAPI activity: 56% and 50% 
residual PAPI activity remained at 10% v/v methanol and DMSO, respectively. Chemical 
modification with dimethyl suberimidate gave only 20% recovery of initial activity and did not 
stabilize the enzyme. Polyol and other stabilizing additives were investigated: activity and 
stability increased with xylitol but not with trehalose, glycerol or ammonium sulphate. PAPI 
displayed Michaelis-Menten kinetics with the fluorescent substrate pyroglutamyl 7-
aminomethylcoumarin at pH 8.0: values for Km and kcat were 0.132 ± 0.024 mM and 2.68 ± 0.11 × 
10-5 s-1 respectively.  
 
Mutant Y147F was notably more thermostable, despite differing from wild type only by the 
absence of a hydroxyl. At 70ºC, the Y147F first-order k value was 0.0028 ± 0.001 min-1 (half-life 
25 min) compared with 0.079 ± 0.003 min-1 (half life 9 min) for wild type (the higher temperature 
was required to achieve timely inactivation of Y147F). Values of Km and kcat for Y147F (0.115 ± 
0.019 mM and 2.45 ± 0.05 × 10-5 s-1 respectively) closely resembled those of wild type.  
 
It appears that the in vitro stability of wild type PAPI might limit its potential applicability in 
peptide processing or other fields. Additives and chemical modification seem to have limited 
scope for enhancing its stability but the generation of stabilized mutant variants, or the use of a 
thermophilic counterpart, should be explored further. 
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Abbreviations 
ACN, acetonitrile; ALT, Alanine aminotransferase; AMC, 7-Amino-4-methyl-coumarin; BCA, 
Bicinchoninic acid; BSA, Bovine serum albumin; C50, Solvent concentration where 50% of 
enzyme activity in aqueous buffer remains; DMF, Dimethylformamide; DMSO, 
Dimethylsulphoxide; DMS, Dimethyl suberimidate; DTT, Dithiothreitol; EDAC, N-(3-
Dimethylaminopropyl)-N’-ethyl carbodiimide; EDTA, Ethylene diamine tetra-acetic acid; F16Y, 
PAPI mutant Phe16→Tyr; GRH, Gonadotropin releasing hormone; HRP, Horseradish 
peroxidase; HPLC, High performance liquid chromatography; IPTG, Isopropyl-beta-D-
thiogalactopyranoside; k, First-order decay constant; LB, Luria-Bertani medium; LHRH,  
Luteinizing hormone-releasing hormone; MeOH, Methanol; MEROPS, the peptidase  database 
at http://merops.sanger.ac.uk/; N, Native state of protein; β-NA, β-Naphthylamine; NEM, N-
Ethylmaleimide; PAPI , Pyroglutamyl peptidase I (E.C.3.4.19.3); PAPII, Pyroglutamyl peptidase 
II (E.C.3.4.19.6); pGDMK, pGlu diazomethyl ketone; pGCK, pGlu chloromethyl ketone; pGlu, 
Pyroglutamic acid; pGlu-AMC,  Pyroglutamyl-7-amino-4-methyl coumarin; pNa, p-Nitroanilide; 
RIA,  Radioimmunoassay; SDS, sodium dedecyl sulfate; T50, Half-inactivation temperature; t½, 
Half-life (0.693/k); THF, Tetrahydrofuran; TRH, Thyrotropin releasing hormone; Y147F, PAPI 
mutant Tyr147→Phe; Z, Benzyloxycarbonyl. 
 
Introduction 
Pyroglutamyl peptides, which often comprise up to 40 amino acids, possess an N-terminal 
pyroglutamic acid (pGlu) residue that influences their biological properties. Many reports 
describe the enzymatic formation of pGlu from glutamic acid and glutaminyl peptides (Orlowski 
and Meister 1971). Cyclisation of the N-terminal glutamic acid to pGlu affords these peptides a 
longer half-life than others of similar size (De Gandarias et al, 2000). Many biologically active 
peptides (thyrotropin-releasing hormone (TRH), luteinizing hormone-releasing hormone (LHRH), 
neurotensin, etc.) and proteins have pGlu residues at their N-termini. Only the pyroglutamyl 
aminopeptidases can cleave these amino terminal pGlu. Three types of pyroglutamyl peptidase 
have been found in a wide variety of bacteria and in many plant, animal, and human tissues. 
These are pyroglutamyl peptidase I (E.C 3.4.19.3; PAP I), pyroglutamyl peptidase II (E.C 
3.4.19.6; PAP II) and serum thyroliberinase (E.C 3.4.19.6) (Cummins and O’Connor, 1998; 
Robert-Baudouy and Thierry, 1998). In the brain, the cytoplasmic cysteine peptidase PAP I (EC 
3.4.19.3, the subject of this paper) hydrolyses pGlu-X bonds (where X is any amino acid except 
proline) and is quite distinct from the membrane-bound, tetrameric, exo-acting metallo peptidase 
PAP type II (EC 3.4.19.6) that degrades thyrotropin releasing hormone in a highly specific 
manner (O’Connor and O’Cuinn, 1985).  
 
Classification and occurrence of PAPI 
Pyroglutamyl peptidase I (PAPI, EC 3.4.19.3) is a cysteine omega-exopeptidase that specifically 
removes the amino-terminal pyroglutamyl residue from oligopeptides and proteins. It has been 
used in protein sequencing to unblock proteins and polypeptides with pGlu amino-termini prior to 
Edman degradation and has had several different names, including pyrrolidonyl peptidase, 
pyrrolidone carboxyl peptidase, 5-oxoprolyl-peptidase, pyrase and pyroglutamyl aminopeptidase 
(Cummins and O’Connor, 1998). 
 
PAPI has been found in various plant, animal, and human tissues, but none has yet been found 
in the Saccharomyces cerevisiae genome nor in any fungus. It occurs as a soluble, intracellular 
cytosolic cysteine peptidase with broad specificity for pGlu-substrates in many mammalian 
tissues including human cerebral cortex, kidney and skeletal muscle, rat, bovine and guinea pig 
brain, and in various rat organs including liver (Cummins and O’Connor, 1998). In vertebrates, 
the liver and kidney show relatively high PAPI activities compared with other tissues. PAPI was 
localized in the renal proximal tubules, while an immunohistochemical localization study of PAPI 
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demonstrated intracellular distribution in the pituitary. Known mammalian PAPI sequences 
include those from human (Homo sapiens; Dando et al., 2003) mouse (Mus musculus; Dando et 
al., 2003) and rat (Rattus norvegicus; Abe et al., 2003). 
 
PAPI activity has also been noted in non-mammalian sources such as bird, fish and amphibian 
tissues. Among plants, it occurs in parsley, carrot, bean, oats, wheat, cauliflower, and potato. 
Tissues tested included leaves, seeds, sprouts and roots (Szewczuk and Kwiatkowska, 1970).  
The purification and study of PAPI has been reported from several prokaryotic species, including 
species of Bacillus (Yoshimoto et al., 1993; Awadé et al., 1992a) Pseudomonas fluorescens 
(Gonzalès and Robert-Baudouy, 1994), species of Pyrococcus (Sokabe et al., 2002; Tsunasawa 
et al., 1998), Streptococcus pyogenes (Awadé et al., 1992b; Cleuziat et al., 1992), 
Mycobacterium bovis (Kim et al., 2001), Staphylococcus aureus (Patti et al., 1995), and 
Thermococcus litoralis (Singleton et al., 2000). The sequences of bacterial and archaeal PAPI 
enzymes place them in peptidase family C15 of the MEROPS classification (Barrett and 
Rawlings, 2001).  
 
Substrates, catalysis and inhibitors  
PAPI hydrolytically removes L-pGlu from L-pGlu-L-X, where X is any amino acid (except proline), 
a peptide or an arylamide such as AMC. PAPI has a broad pyroglutamyl substrate specificity, 
with its activity being influenced by the amino acid directly after the pGlu residue. Synthetic 
compounds and dipeptides such as pGlu-AMC, pGlu-Ala, pGlu-pNa, pGlu-βNA and pGlu-Val are 
also substrates for the enzyme but pGlu-Pro bonds are normally not hydrolysed by mammalian 
PAPI (Cummins & O’Connor, 1996; Browne & O’Cuinn, 1983). Abe et al. (2004a,b) have shown 
that PAPI can tolerate some single atom substitutions on the pGlu ring. Due to the catalytic 
importance of its cysteine thiol group, PAPI has an absolute requirement for a thiol-reducing 
agent such as DTT and loses activity when treated with micromolar concentrations of a standard 
thiol inhibitor such as N-ethylmaleimide (NEM) or iodoacetate (Cummins & O’Connor, 1996; 
Tsunasawa et al, 1998; Singleton et al, 2000; Singleton & Littlechild, 2001; Dando et al, 2003). 
The additional involvement of a histidine and of acidic residues in catalysis was indicated by 
chemical modification studies with diethylpyrocarbonate and N-(3-Dimethylaminopropyl)-N’-ethyl 
carbodiimide (EDAC) respectively (Le Saux et al, 1996). Several specific inhibitors have been 
synthesized to elucidate the biological significance of the enzyme (Fujiwara et al, 1981; 
Friedman et al, 1985), including pGlu chloromethyl ketone (pGCK), Z-pGlu chloromethyl ketone 
(Z-pGCK), and Z-pGlu diazomethyl ketone (Z-pGDMK). Charli et al. (1987) reported that 
pGDMK did not enhance brain TRH levels in vivo or in vitro, but Faivre-Bauman et al. (1986) 
observed increased levels of TRH when primary hypothalamic cell cultures were treated with Z-
Gly-Pro-CHN2, another PAPI inhibitor. Fujiwara et al. (1981) noted a decrease in enzyme activity 
upon addition of pGCK in the absence of DTT. A synthetic aldehyde analog of pGlu, 5-
oxoprolinal, was a potent competitive inhibitor of PAPI (Friedman et al, 1985). Several other 
inhibitors of mammalian PAPI exist. Yamada and Mori (1990) noted the inhibitory effects of 1,10-
phenanthroline, excess DTT and EDTA while Cummins and O’Connor (1996) reported 28% 
inhibition of bovine brain PAPI by 1mM 1,10-phenanthroline. Two compounds isolated from the 
genus Streptomyces, benarthin and pyrizinostatin, acted as inhibitors of PAPI (Aoyagi et al, 
1992a,b) as did an oligosaccharide gum from Hakea gibbosa (Alur et al, 2001). Mantle et al. 
(1991) noted inhibitory effects of amastatin, arphamenine, chymostatin, elastinal and leupeptin 
while benzamidine inhibited the bacterial PAPI enzyme (Awadé et al, 1994). Several workers 
have used the selective reversible inhibitor 2-pyrrolidone to stabilize type I pyroglutamyl 
peptidases during purification and storage (Mudge & Fellows, 1973). 
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Characterization 
The molecular weight of PAPI monomer has mostly been reported as around 24 kDa by gel 
filtration and denaturing gel electrophoresis. Optimal activity lies in the pH range 6.0 to 9.5 and, 
where reported, the isoelectric point (pI) is around 5.0. Optimum temperatures for activity of 
mesophilic prokaryotic PAPI have mostly been reported as ranging from 30 - 45ºC (37ºC has 
been widely used as the standard reaction temperature for eukaryotic PAPI) but two thermophilic 
enzymes from Thermococcus litoralis PAPI and Pyrococcus furiosus PAPI exhibit optimum 
activity at 70ºC and 90ºC, respectively. (Singleton & Littlechild, 2001; Ogasahara et al, 2001). 
Purification of PAPI from several strains of Bacillus has been well documented. Bacillus 
amyloliquefaciens PAPI has been particularly well studied, including cloning, sequencing and 
expression of its gene in Escherichia coli. The enzyme comprises 215 amino acid residues, has 
a homodimer structure with a deduced subunit molecular mass of 23.3kDa and a pH optimum of 
6.5. (Yoshimoto et al, 1993; Ito et al., 2001).  
 
Physiological role(s) 
The physiological role of PAPI currently remains unclear. Its cytosolic location excludes a 
significant role in extracellular peptide degradation (Charli et al., 1987; Abe et al., 2004a,b). 
O’Cuinn et al. (1990) suggested that PAPI may represent a mechanism for returning pGlu 
terminating neuropeptides, released from damaged or ageing vesicles, back to the cellular 
amino acid pool. PAPI may participate in the intracellular catabolism of peptides to free amino 
acids which are then re-incorporated into biosynthetic pathways. Thus, PAPI may function in 
regulating the cellular pool of free pGlu. In mammals, it may be involved in the inactivation of 
biologically active peptides with an N-terminal pGlu, such as TRH, LHRH, bombesin, 
neurotensin, gastrin, fibrinopeptides and anorexigenic peptide (Alba et al, 1995). PAPI may also 
contribute to the inactivation of neuropeptides that are produced in excess. Faivre-Bauman et al. 
(1986) showed that addition of specific PAPI inhibitors to cultured TRH-synthesising 
hypothalamic cells significantly increases TRH content and release from cells under both basal 
and K+-stimulated conditions. PAPI is involved in the hydrolysis of some xenobiotic compounds 
with an L-pGlu or L-pGlu-related structures (Abe et al, 2003; 2004b) and may also be involved in 
detoxification of pGlu-peptides, since high levels of such peptides would abnormally acidify the 
cell cytoplasm. The high level of Pyroglutamyl Peptidase in the human brain cortex agrees with 
the observation that inactivation of TRH is higher in the human brain cortex than in other regions 
(Griffiths, 1985).  
 
Roles in health and disease 
A correlation between PAPI activity and TRH levels in mammalian brain has been observed in 
many studies (De Gandarias et al, 1998; 2000). A decrease in PAPI activity coincides with 
increasing levels of TRH as brain development progresses, indicating that PAPI plays a part in 
the normal development of mammalian brain. The wide distribution of TRH throughout the 
central nervous system and the findings of various biochemical, pharmacological and 
behavioural studies strongly implies that TRH may act as a neuromodulator or neurotransmitter 
in the extrahypothalamic brain. Also, during earlier stages of development, high PAPI activity is 
linked to elevated levels of cyclo(His-Pro) (Prasad et al, 1983). In addition to its better-known 
neurohormonal role, PAPI may also have an important part to play in memory and learning, in 
metabolism and the possible control of conditions such as Alzheimer's disease (Irazusta et al, 
2002). 
 
The effect of light intensity on the activity of PAPI in the functionally connected rat retina and 
hypothalamus was studied by Ramírez et al. (1991) and Sánchez et al. (1996). PAPI levels 
fluctuate periodically, coincident with environmental light and dark conditions, suggesting a 
possible function of PAPI within the human “body clock” (Sanchez et al. 1996). Substrates of 
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PAPI (such as TRH or LHRH) may play a functional role in the retina, apart from their well-
known role in the hypothalamus. The concentration of TRH in the hippocampus of elderly 
controls and AD patients was recorded by radioimmunoassay (RIA). He and Barrow (1999) 
reported that PAPI may be involved in the propensity of amyloid precursors to form insoluble 
plaques, resulting in Alzheimer-type diseases. Free pGlu is known to have pharmacological 
properties and these have been demonstrated in certain disease states (Lauffart et al., 1989; 
Mantle et al., 1990; 1991).  
 
Active Site  
The active sites of cysteine proteases typically have a catalytic triad, an oxyanion hole and a 
specificity pocket. The catalytic triad of B. amyloquefaciens PAPI comprises Cys144, His168 and 
Glu81 (Odagaki et al., 1999), as confirmed by site-directed mutagenesis of the appropriate 
amino acids. Previously, the two cysteine residues of B. amyloquefaciens PAPI, Cys68 and 
Cys144, had been mutated to Ser. Mutant Cys144→Ser had no detectable PAPI activity 
(Yoshimoto et al., 1993), while Cys68→Ser had wild type activity, implicating Cys144 as the 
active site thiol. Also, titration with 5,5'-dithio-bis-(2-nitrobenzoate) showed that Cys68 is located 
internally. His168 is also completely conserved, and thus PAPI was thought to be a cysteine 
protease with a Cys-His catalytic diad or Cys-His-Asp/Glu catalytic triad. 
 
Le Saux et al. (1996) investigated several candidate active site residues of Pseudomonas 
fluorescens PAPI. Substitution of residues Cys144 and His166 by Ala and Ser, respectively, 
resulted in inactive enzymes. Proteins with changes of Glu-81 to Gln and Asp-94 to Asn were 
not detectable in crude extract and were probably unstable in bacteria. The results suggest that 
Cys-144 and His-166 constitute the nucleophilic and imidazole residues of the enzyme active 
site, while residue Glu-81, Asp-89, or Asp-94 might constitute the third part of the active site (see 
below). Tsunasawa et al. (1998) substituted Cys142 of P. fluorescens PAPI with Ser, resulting in 
inactive enzyme and showed, by sequence analysis, that the catalytic triad Cys142-His166-
Glu79 corresponds to Cys144-His168-Glu81 of B. amyloquefaciens PAPI. The location of the 
Cys144 at the N-terminus of an α-helix could be important. Such a position could affect 
catalysis, as the helix dipole can depolarise the amide bond and enhance its reactivity.  
 
PAPI does not have a well defined oxyanion hole; however, it is possible that a tetrahedral 
oxyanion could be produced by the contribution of Cys144 and Arg91 and their respective side 
chains. A hydrophobic region close to Cys144 provides a highly specific binding site for the pGlu 
of the enzyme's substrate. This pocket appears to have some conformational flexibility, hence 
allowing for maximum interaction with the substrate. PAPI appears to have only one pocket of 
specificity (Odagaki et al., 1999). The catalytic residues Glu81, Cys144, and His166 of the B. 
amyloliquefaciens enzyme are conserved in the human sequence (Dando et al, 2003). 
 
Structure 
Native mammalian PAPI appears to be monomeric, but molecular mass values of 50–91 kDa, 
consistent with a dimer, have been reported for the bacterial enzyme. The recombinant B. 
amyloliquefaciens enzyme probably functions as a dimer (Yoshimoto et al., 1993) but has been 
crystallised as a tetramer (Odagaki et al., 1999) while crystalline PAPI from Thermococcus 
litoralis is also tetrameric (Singleton et al., 1999a,b).  
 
The first documented X-ray crystal structures of bacterial PAPI were at 1.6 Å for Bacillus 
amyloliquefaciens (Odagaki et al., 1999), at 1.73 Å for Pyrococcus furiosus PAPI (Tanaka et al., 
2001), at 2.0 Å for Thermococcus litoralis PAPI (Singleton et al., 1999a,b) and at 2.2 Å for 
Pyrococcus horikoshii PAPI (Sokabe et al., 2002). The monoclinic crystal form of each one has 
four crystallographically independent copies of PAPI in the asymmetric unit, and comprises a 
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tetramer of four identical subunits designated A-D. Each monomer of the tetramer makes 
contact with two other subunit monomers. The A-D interface of Bacillus amyloliquefaciens PAPI 
involves hydrophobic interactions and several ionic salt bridges between each monomer. The A-
C interface does not have any ionic salt bridges and a thin layer of water mediates hydrogen 
bonds between the subunits (Odagaki et al., 1999).  
 
The polypeptide folds in an α/β  globular domain with a hydrophobic core comprising a twisted β- 
 sheet surrounded by five α- helices. This structure allows the function of most of the conserved 
residues in the PAPI family to be identified, and it seems that the catalytic triad comprises 
Cys144, His168 and Glu 81 (see above) situated inside the doughnut-shaped tetramer.  
 
The Thermococcus litoralis PAPI tetramer has a central cavity of 6000 Å3 (Singleton et al., 
1999a,b). The A-B interface has hydrophobic interactions and salt bridges involving Arg81, 
Asp88, Asp101 and Arg119. The A-C interface is formed by an extended loop and a disulphide 
bridge exists between Cys190 of each monomer. This hydrophobic core may contribute towards 
the thermostability of Thermococcus litoralis PAPI. Other residues along this interface are 
generally hydrophobic. 
 
The A-B interface of the Pyrococcus horikoshii PAPI tetramer also involves hydrophobic 
interactions but there are, in addition, inter-subunit ionic bonds while the A-C interface has 
hydrogen bonds that are entirely mediated by a thin layer of water; however, the enzyme was a 
dimer in solution (Sokabe et al., 2002). 
 
PAPI Wild Type and Mutant Y147F as Candidates for Study 
Recombinant human PAPI may have use in protein sequencing and/or in processing of 
peptides, and possibly in enzymatic peptide synthesis for the attachment of N-terminal pGlu 
residues. A thorough understanding of its stability and catalytic properties would be needed for 
any such applications. This paper reports a study of recombinant human PAPI and its single-site 
mutant Y147F, previously cloned, characterized and over expressed in E. coli (Vaas, 2005), with 
regard to their stabilities at elevated temperatures and kinetics with the chromogenic substrate 
pGlu-AMC. In addition, the stability of the wild type recombinant to organic solvents, and the 
effects on it of additives and of a crosslinking reagent, were also investigated. 
 
Materials and Methods 
Fisher Scientific supplied glacial acetic acid, acetone, EDTA, ethanol (100% v/v), glycerol, HCl 
(37% v/v), NaCl, NaOH, Tris-(hydroxymethyl) aminomethane (Tris) and the HPLC grade 
solvents acetonitrile (ACN), dimethylformamide (DMF) and tetrahydrofuran (THF). BCA 
(Bicinchoninic acid) protein assay kit was from Pierce Chemicals while pyroglutamyl-7-amino-4-
methyl coumarin (pGlu-AMC) was sourced from Bachem. Sigma-Aldrich supplied His-Select 
nickel affinity gel, 7-amino-4-methylcoumarin (AMC), bovine serum albumin (BSA), Bradford 
reagent, dimethylsulphoxide (DMSO, HPLC grade), D,L-dithothreitol (DTT), ampicillin, IPTG, 
imidazole, dimethyl suberimidate (DMS), N-ethylmaleimide (NEM) and any other chemicals 
mentioned, which were reagent grade unless otherwise noted. 
 
We used E. coli XL-10 Gold cells to express PAPI activity. Yeast extract and tryptone for the LB 
growth medium were from Oxoid UK. The cells contained the 5235 bp plasmid pRV5 encoding 
Homo sapiens PAPI (GenBank accession number AJ278828) as a 680 bp rHsa-pap1-(His)6 
fusion (via a Gly-Ser linker) under control of the Ptac promoter (Vaas, 2005). This plasmid is 
very similar to pZK3, encoding bovine PAPI, described by Kilbane et al. (2007). The differences 
are located within the 680 bp segment, bounded by EcoR1 and HindIII sites, that codes for the 
fusion protein: an EcoRV restriction site at 406 bp replaces the EagI site at 553 bp in pZK3 and 
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the corresponding human amino acid residues (in brackets) are present at positions 81 (Thr), 
205 (Tyr) and 208 (Lys). Commercial DNA sequencing (MWG Biotech, Germany) verified the 
exact sequence of pRV5 and of the single-site PAPI mutant, Y147F.  
 
Production and Purification of Recombinant PAPI  
LB growth broth (100ml, containing ampicillin to 100µg.ml-1) was aseptically inoculated with 3ml 
of overnight culture of E.coli XL-10 Gold harboring pRV5 and incubated at 37°C. Once the cells 
reached exponential phase (A600 0.3-0.5), the inducer IPTG was added to 0.05 mM. 
Recombinant protein production continued for 5 h or overnight. Cells were then centrifuged 
(3200 × g), the supernatant decanted, and the cell pellet labelled and stored at 4°C until 
required. The pellet was re-suspended in 10ml of buffer (50mM potassium phosphate, pH 8.0). 
The sample was then sonicated on ice (2.5 pulses.s-1, 220 W, amplitude 40, 15 min), centrifuged 
(3200 × g) to remove cell debris and the clear protein lysate supernatant was retained. Ni2+ resin 
(1ml) was added to the protein lysate, which was mixed with shaking for 1 h then poured into a 
column. Potassium phosphate buffer (50mM, pH 8.0, 10ml) was then run through the column 
three times?. Next, wash buffer (50mM potassium phosphate, pH 8.0, containing 20mM 
imidazole, 20ml) was applied three times?. Finally, elution buffer (50mM potassium phosphate 
buffer, pH 8.0, containing 200mM imidazole, 20ml) was run through the column three times? to 
release PAPI (wild type or mutant Y147F, as appropriate). PAPI-containing fractions were 
combined, mixed with glycerol (40% v/v final concentration) and stored at 4°C until required. 
Purified PAPI typically had a specific activity of 0.34 U.mg-1 (where 1 U = 1 nanomol AMC.min-
1.ml-1) and gave a single 23-24 kDa band on denaturing gel electrophoresis (Laemmli, 1970). 
Specific activity of mutant Y147F was 0.83 U.mg-1. Protein concentrations were measured by 
either the standard BCA protein assay (Smith et al., 1985) or the Bradford method (Bradford, 
1976). 
 
Quantitative Fluorimetric Measurement of PAPI Activity  
The PAPI activity assay was according to Fujiwara and Tsuru (1978) as modified by Browne and 
Ó’Cuinn (1983). Each PAPI sample (25µL, in triplicate) was placed into separate wells of a 96-
well fluorometer microplate and 100µL of the assay solution (50 mM potassium phosphate 
buffer, pH 8.0, containing final concentrations of 10 mM DTT, 2 mM EDTA and 0.5 mM pGlu-
AMC) was added to each well. (Residual concentration of DMSO (required to prepare the 10 
mM pGlu-AMC stock solution) in the assay mix did not exceed 5% v/v). The microplate was 
incubated at 37°C for 30 min; then, 1.5M acetic acid (100µL) was added to each well to arrest 
enzyme activity. Liberated AMC was measured using a Perkin Elmer LS-50 fluorescence 
spectrometer with excitation at 370nm and emission read at 440nm. Fluorescence readings 
were converted to nanomol of AMC released per minute using an AMC standard curve prepared 
under identical conditions. In addition to buffer, standard curves were determined in the 
presence of 10% (v/v) DMF, culture medium and of imidazole and also using crude and purified 
PAPI suspensions. Experimental values were determined using the most appropriate standard 
curve. The assay was shown to be linear with respect to time and amount of added PAPI (r² = 
0.99 in both cases). 
 
Kinetic Analysis 
pGlu-AMC (10mM in DMSO) was diluted to 0.5mM with 50mM potassium phosphate buffer, pH 
8.0. This solution was further diluted in buffer to give a range of pGlu-AMC concentrations and 
purified PAPI was assayed at each substrate concentration. The Michaelis-Menten constant (Km) 
and maximum velocity (Vmax) values were determined using the Enzfitter programme (Biosoft, 
Cambridge, UK). A similar procedure was followed for mutant Y147F. 
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Active site titration was based on Turk et al. (1993) but used N-Ethylmaleimide (NEM) instead of 
their E-64. A range of NEM concentrations (0-2.5µM, prepared by dilution of a 1mM stock 
solution with ultra-pure water) were used to titrate activated PAPI. At each point, 25µl of purified 
PAPI (diluted appropriately with 50mM potassium phosphate buffer, pH 8.0) was mixed with an 
equal volume of NEM solution, brought to a total volume of 100 µl with 50mM potassium 
phosphate buffer, pH 8.0, and incubated at 37°C for 15 min. Residual activity was then 
determined in triplicate. Fluorescence intensity was plotted versus NEM concentration and the 
operational molarity of PAPI determined. A similar procedure was followed for mutant Y147F. 
 
Thermal Stability 
Samples of purified PAPI (0.45 mg.ml-1 stock diluted appropriately in 50mM potassium 
phosphate buffer pH 8.0 to yield a suitable range of fluorescence units in the activity assay) were 
incubated for 10 min at temperatures between 30º-80ºC, then placed on ice prior to re-warming 
and assay of the remaining PAPI activity in triplicate at 37oC.  Buffer-only blanks were also 
prepared. A plot of % residual activity against temperature (°C) was constructed to give a 
thermal profile and the T50 (half-inactivation temperature) determined by inspection.  
PAPI samples, prepared similarly, were placed in a waterbath held at 60ºC. Aliquots were 
removed at intervals, cooled rapidly on ice and the remaining PAPI activity assayed as above 
following re-warming. Residual activity (%, calculated from the sample’s initial activity) was 
plotted versus time. Data were fitted to a first-order exponential decay using Enzfitter (Biosoft, 
Cambridge, UK) to estimate the rate constant (k) and, hence, the half-life (t½; 0.693/k). PAPI and 
mutant Y174F were tested similarly at 70ºC in buffer containing 0.12 mg.ml-1 BSA to ensure a 
uniform protein concentration. 
 
Tolerance of Organic Solvents 
PAPI samples, prepared as above, were incubated for 1 h at room temperature with various 
solvents (ACN, DMF, DMSO, THF, methanol, ethanol) ranging in concentration from 0-90% (v/v) 
in 50mM potassium phosphate pH 8.0 in a final volume of 1ml. Enzyme-free blanks were also 
set up for each solvent at each v/v concentration. The samples were then assayed in triplicate 
under normal conditions and a plot of % remaining activity versus solvent concentration (% v/v) 
was constructed.  
 
Chemical Modification 
The protocol was based on de Renobales and Welch (1980). Purified PAPI (0.45 mg.ml-1) was 
diluted with 50 mM potassium phosphate, pH 8.0 (3ml). A stock solution of dimethyl 
suberimidate (DMS; 2.5 mg.ml-1) was similarly diluted and was mixed with with an equal volume 
of PAPI (final concentrations: DMS 25 µg.ml-1; PAPI 5 µg.ml-1). PAPI-DMS and a control were 
incubated at room temperature for 30 min. A thermal profile was then determined for each and 
plots of % residual activity versus temperatures were prepared. 
 
Effects of Additives 
Ammonium sulfate, trehalose and xylitol were each added to 0.5 M final concentration to 
separate samples of PAPI (5 µg.ml-1 final concentration). Thermal profiles were determined and 
plots of % residual activity versus temperature prepared in each case. The effects of 10% v/v 
and 50% v/v glycerol were determined similarly. 
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Results and Discussion  
Thermal Stability 
The temperature profile (Figure 1) showed that PAPI activity declined above 45°C. The half-
inactivation temperature (T50, value where observed activity was 50% of maximal) was estimated 
by inspection to be 60°C ± 1°C.  
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Figure 1: A temperature profile of PAPI. 
Plot of % residual activity versus temperature (°C), following 10 min incubations at each 
temperature. Activity is represented as a percentage of the 30ºC value. 
 
Data of % residual activity versus time at a uniform 60ºC fitted well to a first order exponential 
decay to yield a k value of 0.046 ± 0.002 min-1 and, hence, a half-life (t½) of 15 min. Human PAPI 
expressed in Sf9 insect cells was stable at temperatures up to 40°C for 4.5 h, but activity was 
almost completely lost within 30 min at 60°C, in line with the present results. Maximal activity 
was seen at 50°C in 10 min assays (Dando et al., 2003), a somewhat higher temperature than 
our value of 45°C; the different values may arise from the use of different buffer compositions or 
protein concentrations. Many glycosylated polypeptides, both native and recombinant, are more 
heat-stable than their ‘naked’ counterparts expressed in E. coli. One potential N-glycosylation 
motif, Asn-Ala-Ser, occurs at positions 25-27 of human PAPI. Possibly, the insect cells used by 
Dando et al. (2003) perform a post-translational glycosylation of PAPI. Molecular mass values 
(Dando et al., 2003), however, suggest that glycosylation, if it indeed occurs, is not extensive.  
 
Thermal stability of PAPI varies with the temperatrures preference of the source organism. The 
temperature-activity profile of PAPI from the hyperthermophilic archaeon Thermococcus litoralis 
has a maximum at 70°C, where it has a half-life of 1 h. Although considerably more 
thermostable than mesophilic enzymes, T. litoralis PAPI loses its activity rapidly at temperatures 
>80°C. This is likely to be due to destruction of the critical cysteine in the active site (Singleton et 
al., 2000). PAPI from the hyperthermophilic archaeon T. litoralis showed enhanced thermal 
stability over that of mesophilic B. amyloliquefaciens, probably due to the presence of inter 
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subunit disulphide bonds. B. amyloliquefaciens PAPI with an engineered inter-subunit disulphide 
bond showed increased thermal stability, without any decrease in enzymatic performance. 
However, pH stability was not altered (Kabashima et al., 2001). The thermophilic  PfuPAPI 
exhibits optimum activity at  90ºC  (Ogasahara et al., 2001). 
 
Resistance to Solvents 
PAPI was unstable in most of the water-miscible, hydrophilic solvents tested. The C50 values 
(the % v/v concentration leading to half-inactivation versus aqueous buffer) for the least injurious 
solvents DMSO and methanol were 10% v/v and 12% v/v, respectively (errors ± 0.5 % v/v).  
THF, a strong denaturant, had a notably adverse effect even at 10% (v/v): activity declined 
sharply to about 1/10 of the aqueous level. Results with DMF were similar: at 10% (v/v) DMF, 
activity was 26% of that in aqueous buffer, while at 20% (v/v) DMF only 10% of the aqueous 
activity remained. PAPI activity declined to 21% of that in aqueous buffer at 10% (v/v) ACN. In 
10% (v/v) acetone, residual activity was 33%, while above 50% (v/v) concentration, no 
significant PAPI activity remained. Ethanol at concentrations of 10% and 20% (v/v) reduced 
activity to 40% and 29%, respectively, of that in aqueous buffer. At ≥40% (v/v) ethanol, virtually 
no activity remained.  
  
 
Figure 2: Effect of water-miscible solvents (10 and 20% v/v) on PAPI activity 
Plot of % residual activity versus 10 or 20 (% v/v) solvents concentration. 
(■) Solvents concentration 10 % (v/v), (■) solvents concentration 20 % (v/v) 
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Chemical Modification with Dimethyl Suberimidate (DMS) 
A temperature profile indicated that chemical modification with DMS rendered PAPI less 
thermostable than native at the same concentration. Only 20% of the initial PAPI activity 
remained following DMS treatment, a very low recovery. This poor outcome was unexpected: 
DMS is a very mild protein modifying reagent which should not lead to significant inactivation. 
DMS treatment has effectively stabilized other enzymes such as horseradish peroxidase (HRP, 
4-fold increase in t½ at 75ºC; Ryan et al., 1994) and alanine aminotransferase (16-fold increase 
in t½ at 35ºC; Moreno and Ó’Fágain, 1997). DMS usually reacts with Lys/ -NH2 groups of 
proteins only and not with any other R-groups (Ji, 1983). There are 10 Lys residues in human 
PAPI, 3 of which lie within conserved sequences (R Larragy, unpublished); modification of a 
conserved Lys could compromise the enzyme’s activity and/or stability. 
 
Effects of Ammonium Sulfate and of Polyols on PAPI Activity and Stability 
Contrary to expectation, ammonium sulfate had no stabilising or protective effect on PAPI at any 
of the temperatures tested. PAPI activity was significantly reduced at 0.5 M ammonium sulfate, 
with 35% less activity displayed than in buffer. Activity of a different brain peptidase, the proline-
specific dipeptidyl peptidase IV (DPPIV; EC 3.4.14.5) from bovine brain, was also significantly 
reduced (80%) in presence of 1M ammonium sulfate compared with buffer alone (Buckley, 
2001). 
 
Glycerol also inhibited PAPI: only 50% of aqueous activity was manifested in 10% (v/v) glycerol 
and a mere 18% activity at 50% (v/v) glycerol. Except for a marginal effect >60oC at an inhibitory 
50% (v/v), glycerol had no protective or stabilizing effect on PAPI at elevated temperatures. 
 
It was hoped that PAPI would be stabilized against heat by the inclusion of xylitol or trehalose 
(Schein, 1990). Trehalose prevents proteins from denaturing at high temperature in vitro. It also 
suppresses the aggregation of denatured proteins, maintaining them in a partially-folded state 
from which they can be reactivated. The continued presence of trehalose, however, interferes 
with refolding (Singer and Lindquist, 1998) Trehalose (0.5M) did not stabilize PAPI. 
 
Xylitol at 0.5M gave a significant increase in PAPI activity at 30°C and 40°C. With xylitol, PAPI 
retained >50% activity at 60ºC while, in its absence, the T50 was 45ºC. A protecting effect was 
also evident during thermoinactivations at 60ºC where t½ was 60% longer with xylitol (first-order 
k-values in presence and absence of xylitol were 0.05 ± 0.002 min-1 (t½ 14 min) and 0.08 ± 0.003 
min-1 (t½ 9 min) respectively). Note that the protein concentrations in these experiments were 
less than in the thermal inactivations described above, hence the different values for the PAPI 
controls. 
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Figure 3.    Effect of Xylitol on PAP1 
Plot of % residual PAP1 activity versus temperature (°C). (♦) without xylitol; (■) with xylitol. 
Activity is represented as a percentage of the 30ºC value in each case. 
 
Thermal Stability and pGlu-AMC Kinetics of Mutant Y147F 
Tyr 147 of PAPI is located in the substrate binding site, very close to the catalytic Cys 149 
(Vaas, 2005). Comparison of 13 known eukaryotic PAPI amino acid sequences shows that both 
of these residues lie within a conserved sequence DAGRY147LC149DFTYYTSLY. At the 
equivalent position in prokaryotes, Phe occurs instead of Tyr in 25 of 37 sequences (R Larragy, 
unpublished). Both Phe and Tyr have phenyl R-groups but Tyr possesses a hydroxyl group on 
its benzene ring. Hydroxyls can participate in hydrogen bonding at moderate pH values or 
undergo ionization at strongly alkaline pH. We were curious, therefore, to investigate the effects 
of a Tyr147→Phe mutation.  
 
Thermoinactivation of both wild type PAPI and Y147F (diluted appropriately in 50mM potassium 
phosphate buffer, pH 8.0, containing 0.12mg.ml-1 BSA to ensure a constant protein 
concentration) was studied at 70ºC over 80 min. (The higher temperature was required to 
achieve timely inactivation of Y147F.) Under these conditions, t½ for Y147F was 25 min, almost 
3 times longer than that of wild type PAPI (9 min; see Table 1). Remarkably, removal of the –OH 
group from position 147 has a very stabilizing effect on PAPI, perhaps due to improved 
hydrophobic packing.  
 
Michaelis-Menten Kinetics of PAPI and Y147F on pGlu-AMC 
Both wild type PAPI and mutant Y147F utilized the convenient fluorimetric substrate pGlu-AMC 
and displayed Michaelis-Menten kinetics. Use of NEM, a thiol-directed reagent, allowed 
calculation of the active sites contents [E] and, hence, calculation of the respective kcat values 
from the experimentally-determined Vmax, since kcat = Vmax/[E]. Table 1 presents the calculated 
values. The amidase activity showed a kcat/Km value for PAPI of 0.202 (s-1 M-1) while the 
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corresponding value for Y147F was 0.212  (s-1 M-1). These values are virtually identical, showing 
that loss of the –OH from position 147 does not affect cleavage of pGlu-AMC.  
 
  
Table 1.  Comparison of Native PAPI with Variant Y147F. 
 Native PAPI Mutant Y147F 
First-order k-value (min-1), 70°C  0.079 ± 0.003 0.028 ± 0.001 
Half-life (t½), 70°C 9 min 25 min 
Protein content (mg.ml-1) 0.12  0.12  
Km (mM) 0.13 ± 0.02 0.12 ± 0.02 
Vmax (µmol.min-1.ml-1)  0.0013 ± 0.0001 0.0015 ± 0.0002 
Active sites (µM; NEM method) 0.8 1.04 
kcat (s-1) 2.68 × 10-5 2.45 × 10-5 
kcat/Km (s-1.M-1) 0.202 0.212 
 
 
Conclusion 
Themal stability of recombinant human brain PAPI proved considerably higher than would be 
expected for this enzyme, since mammalian pyroglutamyl peptidases normally exist at the 
physiological body temperature of 37°C. PAPI was catalytically active up to quite elevated 
temperatures, with a t½ of 15 min at 60°C. Nevertheless, the in vitro stability of wild type PAPI 
might limit its potential applicability in peptide processing or other fields, since PAPI was 
unstable to most of the water-miscible organic solvents tested. Methanol and DMSO were the 
least injurious to PAPI activity while THF was the most deleterious. Modification of PAPI with 
DMS, a very mild reagent, gave only 20% recovery of initial activity and did not stabilize the 
enzyme. PAPI activity and stability increased with xylitol but trehalose, glycerol and ammonium 
sulphate conferred no benefits. Xylitol, therefore, may be a better preservative for PAPI than 
glycerol, the additive currently used. It would seem that chemical modification and/or additives 
have limited scope to enhance PAPI stability but the use of a thermophilic counterpart, or the 
generation of stabilized mutant variants of recombinant PAPI, should be explored further. The 
latter may indeed be possible, since the single-site mutant Y147F, with a t½ of 25 min at 70°C, is 
notably more thermostable than wild type PAPI. With pGlu-AMC as substrate, the kinetic 
parameters of the two enzymes were virtually identical. 
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